Next Article in Journal
Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution
Next Article in Special Issue
HIV Vaccine Development: 35 Years of Experimenting in the Funding of Biomedical Research
Previous Article in Journal
Meta-Transcriptomic Identification of Divergent Amnoonviridae in Fish
Brief Report

ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study)

1
Pole de Biologie, CHU de Bordeaux, 33076 Bordeaux, France
2
CNRS UMR 5234, Université de Bordeaux, 33076 Bordeaux, France
3
Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, CHU de Bordeaux et Université de Bordeaux, ISPED INSERM U 1219, 33076 Bordeaux, France
4
Laboratoire Bordelais de Recherche en Informatique (LaBri), Université de Bordeaux, 33400 Talence, France
5
Laboratoire d’Immunologie et Immunogénétique, CHU de Bordeaux, 33076 Bordeaux, France
6
CNRS Immuno ConcEpT, Université de Bordeaux, UMR 5164, 33076 Bordeaux, France
*
Author to whom correspondence should be addressed.
Viruses 2020, 12(11), 1256; https://doi.org/10.3390/v12111256
Received: 1 October 2020 / Revised: 2 November 2020 / Accepted: 3 November 2020 / Published: 5 November 2020
(This article belongs to the Special Issue HIV and SARS-CoV-2 Pathogenesis and Vaccine Development)
We proposed a new HIV-1 therapeutic vaccine based on conserved cytotoxic T lymphocyte (CTL) epitopes of archived HIV-1 DNA according to their affinity to the dominant HLA-A and -B alleles of the population investigated. Our proposal (Hla Fitted VAC, HFVAC) was composed of 15 peptides originating from the RT, gag and nef parts of proviral DNA. Our aim was to investigate baseline immune reactivity to the vaccine in HIV-1 chronically infected patients at success of antiretroviral therapy (ART) who would be eligible for a therapeutic vaccine. Forty-one patients were tested. Most of them had been infected with HIV-1 subtype B and all had been receiving successful ART for 2 to 20 years. The predominant HLA-A and -B alleles were those of a Caucasian population. ELISPOT was carried out using the HFVAC peptides. In 22 patients, the PD-1 marker was investigated on CD4+ and CD8+ T cells by flow cytometry in order to evaluate global T cell exhaustion. ELISPOT positivity was 65% overall and 69% in patients exhibiting at least one HLA allele fitting with HFVAC. The percentages of CD4+ and CD8+ T cells expressing PD-1 were high (median values 23.70 and 32.60, respectively), but did not seem to be associated with an impairment of the immune response investigated in vitro. In conclusion, reactivity to HFVAC was high in this ART-treated population with dominant HLA alleles, despite potential cellular exhaustion associated with the PD-1 marker. View Full-Text
Keywords: HIV-1; vaccine; HFVAC; CTL epitopes; archived proviral DNA; HLA I alleles; PD-1; ELISPOT HIV-1; vaccine; HFVAC; CTL epitopes; archived proviral DNA; HLA I alleles; PD-1; ELISPOT
Show Figures

Figure 1

MDPI and ACS Style

Fleury, H.; Caldato, S.; Recordon-Pinson, P.; Thebault, P.; Guidicelli, G.-L.; Hessamfar, M.; Morlat, P.; Bonnet, F.; Visentin, J. ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study). Viruses 2020, 12, 1256. https://doi.org/10.3390/v12111256

AMA Style

Fleury H, Caldato S, Recordon-Pinson P, Thebault P, Guidicelli G-L, Hessamfar M, Morlat P, Bonnet F, Visentin J. ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study). Viruses. 2020; 12(11):1256. https://doi.org/10.3390/v12111256

Chicago/Turabian Style

Fleury, Hervé, Sabrina Caldato, Patricia Recordon-Pinson, Patricia Thebault, Gwenda-Line Guidicelli, Mojgan Hessamfar, Philippe Morlat, Fabrice Bonnet, and Jonathan Visentin. 2020. "ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study)" Viruses 12, no. 11: 1256. https://doi.org/10.3390/v12111256

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop